

Resource Summary Report

Generated by PRECISE-TBI on Aug 10, 2026

Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP Rabbit mAb (Sepharose Bead Conjugate)

RRID:AB_1595393

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3510, RRID:AB_1595393

Antibody Information

URL: http://antibodyregistry.org/AB_1595393

Proper Citation: Cell Signaling Technology Cat# 3510, RRID:AB_1595393

Target Antigen: Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP Rabbit mAb (Sepharose Bead Conjugate)

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: IP. Consolidation on 10/2018: AB_10695597, AB_1595393.

Antibody Name: Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP Rabbit mAb (Sepharose Bead Conjugate)

Description: This monoclonal targets Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP Rabbit mAb (Sepharose Bead Conjugate)

Target Organism: b, drosophilaarthropod, rat, hm, hamster, porcine, h, dm, m, yeastfungi, sc, mouse, r, zebrafishfish, pg, bovine, z, mi, human, mk

Antibody ID: AB_1595393

Vendor: Cell Signaling Technology

Catalog Number: 3510

Record Creation Time: 20250820T000603+0000

Record Last Update: 20250820T072226+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP Rabbit mAb (Sepharose Bead Conjugate).

No alerts have been found for Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP Rabbit mAb (Sepharose Bead Conjugate).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Lin YT, et al. (2024) Targeting acetylated high mobility group box 1 protein (HMGB1) and toll-like receptor (TLR4) interaction to alleviate hypertension and neuroinflammation in fructose-fed rats. British journal of pharmacology.

Chen L, et al. (2023) KLHL7 promotes hepatocellular carcinoma progression and molecular therapy resistance by degrading RASA2. iScience, 26(6), 106914.

Ramakrishnan G, et al. (2022) NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. Cell reports, 41(6), 111623.